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normal. Peripheral pulses were normal. There was 3+ pretibial edema
bilaterally.
Laboratory studies revealed the following data: urinalysis showed a
specific gravity of 1.030, 3+ protein, a pH of 5, and no glucose. The
urine sediment contained 4 to 6 red blood cells, I to 3 white blood cells,
and many coarse granular casts per high-power field. The hemoglobin,
hematocrit, white blood cell Count, and differential were normal. Serum
creatinine was 1.4 mg/dl; BUN, 31 mgldl; serum calcium, 7.2 mg/dl;
serum phosphorus, 4.2 mg/dl; and serum albumin, 2.2 g/dl. Serum
electrolytes, liver function studies, and clotting tests were normal.
Serum immunoelectrophoresis showed a decrease in immunoglobulins.
Total serum hemolytic complement was 224 units, and C3 was 1.34
mg/mi (both within normal limits). Protein excretion was 6.6 g/24 hours.
Three options were considered: (I) treating the patient with 125 mg of
prednisone on alternate days for 2 months without performing a renal
biopsy; (2) carrying out a renal biopsy and treating with the same
program of steroids only if the patient was found to have either the
"minimal-change" lesion or membranous nephropathy; or (3) treating
the patient only with diuretics and avoiding both biopsy and steroid
therapy.
Discussion
Case presentation
A 60-year-old woman who previously had been in excellent health
consulted her physician for periorbital and ankle edema and foamy
urine that she had noticed for one month. Except for the edema, there
were no other abnormal physical findings; the blood pressure was
150/80 mm Hg. A 24-hour urine collection contained 4.5 g of protein, the
serum albumin was 2.7 g/dl, and the serum creatinine was 1.0 mg/dl.
Furosemide was prescribed for edema and the patient was referred to
the Nephrology Clinic at the New England Medical Center.
She had no history of renal disease, diabetes, hypertension, or
hematuria, and protein had never been found in her urine previously.
She had a history of "osteoarthritis" of the hands, but no other joints
had been involved; there was no history of skin rash, chest pain, or
alopecia. She had taken only aspirin as needed for the joint pain. Except
for an occasional dose of Librium, she took no other medications and
had no known exposure to toxins or hazardous chemicals. There was no
family history of renal disease. She was a social drinker and had
smoked I to 2 packs of cigarettes per day for many years.
On examination she was alert and in no distress. Blood pressure was
140/80 mm Hg; pulse was 72/mm. There were some telangiectasias on
the face and chest, and bilateral palmar erythema was present. The
optic fundi were normal; the tongue was not enlarged. Examination of
the heart and lungs was normal. The breasts contained no masses. No
organs were palpable in the abdomen, and percussion revealed a
normal-sized liver. Rectal, pelvic, and neurologic examinations were
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DR. JEROME P. KASS!RER (Professor and Associate Chair-
man, Department of Medicine, Tufts University School of
Medicine, and Associate Physician-in-Chief New England
Medical Center, Boston): Performing a renal biopsy in adults
with the idiopathic nephrotic syndrome (INS) is a diagnostic
tradition from which few physicians deviate [1—4]. Indeed,
there seems to be little justification for breaking with that
tradition. With modern techniques, biopsy is a safe procedure
that reliably provides glomeruli for study, and the glomerular
lesions of INS can be classified neatly into accepted histopatho-
logic entities. More important, the biopsy results determine
whether the patient should be treated: certain histopathologic
entities tend to respond to treatment, whereas others tend not
to. Given the unreliability of clinical features in accurately
predicting the histopathology, renal biopsy has seemed the only
rational approach to the management of INS.
Despite the satisfying logic of this traditional approach, many
thoughtful nephrologists harbor lingering doubts about the
current practice. Is it really necessary that one be certain about
the histopathologic variety of INS before recommending steroid
therapy? Is steroid therapy so dangerous that we should use it
only for patients with lesions known to be steroid responsive?
Is the risk of renal biopsy small enough to justify doing a biopsy
in all patients? Does the value of biopsy justify its risk and
expense? Is a "blind trial" of steroids an appropriate alternate
approach, or would it yield poorer results?
The findings of the renal biopsy, because they identify the
histopathologic variety of INS, merely alter the likelihood of a
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Fig, 1. Primary decision tree for the 60-year-
old woman with idiopathic nephrotic
syndrome (INS) discussed in this Forum. The
choices considered for the patient are those
that emanate from the square (decision) node,
and the outcomes of these choices are chance
events that are represented by circular nodes.
The choices are: supportive therapy only, top
branch; steroid therapy only for the lesions
thought to be steroid responsive on biopsy
(middle branch); and treatment with steroids
for all patients without biopsy (bottom
branch). The presence or absence of a
complication of renal biopsy is represented on
the center branch. Branches that point to®
link to the nephrotic syndrome subtree in
Figure 2; those that point to c link to the
steroid therapy subtree in Figure 3. The
following abbreviations are used: MN, mem-
branous nephropathy; MCD, minimal-change
disease; FGS, focal glomeruloscierosis;
MPGN, membranoproliferative glonierulone-
phritis; Other, all other histopathologic varie-
ties of INS.
steroid-responsive renal lesion. At first blush, the reduction in
uncertainty gained by biopsying the kidney seems highly desir-
able: most would agree that it is always better to know a
diagnosis with certainty rather than to be left guessing. Even if
renal biopsy were totally risk free and totally cost free, howev-
er, this logic would hold true only if the outcome for biopsy-
directed treatment was better on average than the outcome for
the other choices, namely, blind steroid treatment or no treat-
ment at all. If the choice of biopsy-directed treatment is not
clearly preferable, then the expense, discomfort, and inconve-
nience of renal biopsy are not justified [5]. No available clinical
study has addressed this question. The carefully controlled
studies of INS have been designed to determine whether steroid
therapy is better than no treatment for specific histopathologic
lesions. In such studies, all patients are subjected to renal
biopsy. It is impossible to determine the value of renal biopsy
without employing a quantitative approach, because the com-
peting values and risks of the biopsy-directed approach and of
"blind" treatment with steroids are too disparate to compare
them qualitatively.
Decision analysis
Complex clinical decisions such as this typically have been
made intuitively, frequently without full consideration of all the
relevant outcomes. Developments over the past 10 years in the
techniques of decision analysis have made it possible to deal
with difficult clinical questions such as this by comparing
management strategies quantitatively. Decision analysis is
based on probability and utility theory. The method involves
breaking down a problem into several elements: (I) options
available to the decision makers; (2) outcomes of each option;
(3) probabilities of all the outcomes; and (4) values (utilities) of
all the outcomes. When the outcomes, probabilities, and utili-
ties have been specified, one can calculate the average value (or
"expected utility") of all the available options. The strength of
decision analysis as a clinical tool is its quantitative basis.
Although the probabilities required for defining the frequency
of clinical outcomes often are not known with precision, the
method allows one to use the best available approximations of
such data, to specify the range over which these probabilities
vary, and to test the impact on the decision of varying the
probabilities over the specified range. This process, called
sensitivity analysis, is equally applicable to the assessment of
utilities.
The capacity of decision analysis to incorporate data of
diverse types and from diverse sources is one of its potent
advantages. Data describing prevalence of disease, life expec-
tancy, complication rates of tests and treatments, efficacy of
therapy, and quality of life can be synthesized into an integrated
quantitative approach. The totally explicit nature of this method
exposes the structure of a decision, the assumptions, and the
data to open discussion and debate.
I will use decision analysis to assess whether a renal biopsy
should be performed in the 60-year-old woman presented here
today. I will not review the rationale of decision analysis,
pragmatic details of the method, or arguments presented by its
critics; these items can be found in the extensive literature on
the subject [6—31].
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Fig. 2. Nephrotic syndrome subtree that links
to the primary tree in Figure 1 and to the
steroid therapy subtree in Figure 3. This
subtree describes the possible outcomes of the
nephrotic syndrome. Early complications are
represented at the left, persistence or
remittance of the nephrotic state in the center,
and the outcome of renal function at the right.
U refers to utility.
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[ NEPHROTIC SYNDROME SUBTREE
Outcomes Utilities
Structure of the problem
The "decision tree" for the problem posed by this patient is
similar to one used in a recently published study [32] and is
represented in Figures 1 through 3. Figure 1 displays the
primary tree with its three major options, namely, treating all
patients with steroids and not performing renal biopsy (bottom
branch), biopsying the kidney and using the biopsy results to
determine the therapeutic course (middle branch), and neither
biopsying the kidney nor treating the patient with steroids (top
branch). Figures 2 and 3 contain branched extensions (known
as "subtrees") linked to the primary tree at several relevant
points. Figure 2 contains the subtree that describes the possible
outcomes in patients with the nephrotic syndrome. Figure 3
describes the possible outcomes in patients who receive steroid
therapy. The points of attachment of each subtree to its several
relevant positions on the primary tree are denoted by arrows.
One can trace the logic of the decision tree by exploring the
branches of the primary tree and subtrees. I will describe the
data used to designate the outcomes for each subtree later.
Primary tree
For this analysis I have assumed that the possible histopatho-
logic varieties of INS are membranous nephropathy (MN),
minimal-change disease (MCD), focal glomerular sclerosis
(FGS), membranoproliferative glomerulonephritis (MPGN),
and a group of "other" lesions comprising all other disorders.
As already noted, three options are shown in Figure 1. In the
option traditionally chosen, one first biopsies the kidney and
then treats only patients who have either of the two steroid-
responsive lesions, namely, MN and MCD. The middle branch
of Figure 1 illustrates this option. For patients who have a renal
biopsy, one of three possible consequences ensues: (1) no
complications, (2) a nonfatal, biopsy-related complication, or
(3) a fatal complication. If the patient has no complication or
recovers from a nonfatal complication, steroid therapy is given
for lesions known to be steroid responsive (MN and MCD) and
not for those that tend to be steroid unresponsive (FGS,
MPGN, and other). If the patient is not given steroids (top
branch, Fig. 1), the outcomes are a function of the nephrotic
state and the untreated primary renal lesion, whatever it may
be, as illustrated in Figure 2. If the patient is treated with
steroids without having a renal biopsy (bottom branch, Fig. 1),
the outcome is dictated by the consequences of the nephrotic
state, the primary renal lesion, the effect on the kidney of
steroid therapy, and the complications of steroid therapy. The
outcomes of steroid therapy are shown in the subtree in
Figure 3.
Nephrotic syndrome subtree
Figure 2 illustrates the outcomes and utilities for the nephrot-
ic syndrome subtree. I will describe the data for this subtree
later. Irrespective of the renal histopathologic lesion, serious
complications of the nephrotic state—such as thromboembo-
lism, infection, and hypotension—can occur. If the patient
survives one of these complications or has no complication, the
nephrotic state either can disappear (upper branch, Fig. 2) or
persist. If it disappears or if a partial remission ensues, the
patient is not at risk for the development of renal failure or long-
Remission
No nephrotic complications
Nonfatal steroid
complication
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Fig. 3. Steroid therapy subtree that links to both the primary tree and to
the nephrotic syndrome subtree. Symbols are the same as in Figure I.
term complications of the nephrotic state (for example, acceler-
ated arteriosclerosis), and life expectancy is considered normal.
If the nephrotic state persists but the patient's renal function
remains normal (second end branch from the top, Fig. 2), the
patient is at risk only for the long-term complications of
nephrotic syndrome. But if renal function deteriorates (third
end branch), then the patient faces the unpleasant conse-
quences of total renal failure. Because the patient under discus-
sion today first developed INS at age 60 and would not be
expected to develop total renal failure until 5 to 10 years later,
she would not be an ideal candidate for transplantation at that
time. For this reason we assume that her long-term therapy
would consist only of dialysis if renal failure develops.
Steroid treatment subtree
The possible outcomes of steroid therapy are shown in Figure
3. I will describe the data for this subtree subsequently. If
steroids are given, the patient might or might not suffer from a
complication of therapy: if the patient either survives a serious
steroid-related complication or has no such complication, the
outcomes are the same as those described under the nephrotic
syndrome subtree and as displayed in Figure 2. Thus, nonfatal
complications of therapy are incorporated into the decision by a
modification of the utility of each outcome.
Assumptions
In constructing the decision analysis for the 60-year-old
woman described here, many assumptions were made about the
natural history of INS and its modification by therapy. The
definition of INS was based on clinical findings, and obviously
not on the results of a renal biopsy. For our purposes, a patient
has INS if the history, physical examination, and laboratory
studies disclose no secondary cause such as diabetes mellitus,
lupus erythematosus, or drug or heavy-metal exposure. I have
assumed that patients with INS can be categorized histopatho-
logically into the five subgroups contained in the primary tree
(MN, MCD, FGS, MPGN, and other). I further assume that
percutaneous biopsy identifies the histologic subtypes of INS
accurately. Complications of biopsy result either in death or
short-term morbidity. For this analysis we assume no monetary
expense of a renal biopsy.
Outcome measure
In every case the utilities of the outcomes are measured in
Utilities terms of the patient's life expectancy and are adjusted for the
quality of the patient's life. The following assumptions are made
about the quality-adjusted life expectancy in years (QALY): (1)
The worst outcome is early death from any cause (for example,
a complication resulting from biopsy or steroid administration).
This outcome is assigned a QALY of zero. (2) The best outcome
is immediate and permanent remission of nephrotic syndrome
without any complications from diagnostic or therapeutic pro-
cedures. This outcome is given the same value as the patient's
age-, sex-, and race-adjusted life expectancy, in this case, 22.3
years [33]. (3) The early complications of steroid use, of the
_______ nephrotic state, and of biopsy all occur over a limited period
and are incorporated into the decision by subtracting a short
fixed period from the patient's QALY [34]. (4) Factors that
reduce the quality of life over a long period are incorporated
into the decision by reducing the QALY of the patient over time
by a multiplicative factor [34]. If the patient has persistent
nephrotic syndrome, for example, but has an otherwise uncom-
plicated course, and if the quality of life is judged to be reduced
by 10% for the patient because of edema, accelerated arterio-
sclerosis, or other long-term complications, then the age-, sex-,
and race-adjusted life expectancy of 22.3 years would be
multiplied by 0.90 to obtain the QALY for this outcome of 20.1
years. (5) For each outcome, the life of a patient might be
represented by only one segment (for example, permanent
persistent nephrotic syndrome without renal failure) or by two
segments (for example, a period in which the patient has
persistent nephrotic syndrome followed by a period on dialy-
sis). Each of these time intervals would be multiplied by a factor
denoting the quality of life in that segment, and the two
products would be added to obtain the QALY for that given
outcome.
Definition of remission
A reduction in protein excretion to less than 200 mg/day is
defined as complete remission, and to less than 2 g/day is
defined as partial remission. Either type of remission can occur
spontaneously or with steroid treatment. For the purpose of
using a simplifying approximation, I will assume that remission
can occur only within 2 years of treatment. Patients who
experience either a complete or partial remission are considered
to have the same long-term outcome, that is, a normal life
expectancy and a normal quality of life thereafter.
Outcomes of persistent nephrotic syndrome
Patients who fail to achieve a complete or partial remission
have persistent nephrotic syndrome, and over the long term,
such individuals may or may not develop renal failure. Patients
with relapsing heavy proteinuria are considered as having the
same outcomes as do those with persistent proteinuria. The
probabilities of the above outcomes (remission, persistent ne-
phrotic syndrome, late development of renal failure) depend on
the underlying renal pathology, on whether steroids are admin-
istered, and on the effectiveness of steroids.
Early complications of nephrotic syndrome (persistent ede-
ma, hypotension, acute renal failure) lead to short-term morbid-
ity only. I assume that the risk of these complications is
independent of pathologic subtype. Persistent nephrotic syn-
STEROID THERAPY SUBTREE
Outcomes Pointer to
subtree
No complications of
steroid therapy
Non-fatal steroid
complication
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drome produces symptoms and thus reduces the quality of a
patient's life.
Short-term prednisone therapy (125 mg every other day for 2
months) is the only treatment considered. Patients who do not
respond to this regimen are assumed to be unresponsive to any
therapy. Steroid responsiveness either hastens remission in
patients with INS (and thus reduces the frequency of complica-
tions of nephrotic syndrome), reduces the likelihood of eventual
renal failure, or both. Serious complications of steroid therapy
result in either death or short-term morbidity. Some forms of
INS relapse and require more than one course of prednisone
therapy. The probability of complications is taken to be propor-
tional to the number of courses of therapy.
The mean time to the development of renal failure in patients
destined to develop uremia is not altered either by prior biopsy
or steroid therapy. Life expectancy after onset of uremia is
independent of pathologic subtype and previous steroid treat-
ment; it depends only on the age at which uremia begins. The
risk of renal failure is expressed as the probability of uremia
within 10 to 15 years. I selected this interval because data
concerning prognosis within this interval are available for most
of the specific pathologic subtypes of INS. Indeed, there are
few reports with longer follow-up.
Sources of data
As noted before, the data employed in the analysis will be
described according to the tree or subtree in which they are
used. The data consist of probabilities and utilities. In the
following description, the source of these data and the justifica-
tion for their use are provided.
Primary tree
Histopathologic varieties. Bayesian analysis was used to
assess the probability of the various histopathologic varieties of
INS in the patient under discussion today. Bayesian analysis
usually is thought of as a method for combining data on the
prevalence of a disease with that on the sensitivity and specific-
ity of a diagnostic test to estimate the likelihood of a certain
disease being present given a positive or negative test result
[35]. Experience has shown, however, that Bayesian analysis
has even wider applicability: by using other types of clinical
information in addition to data on the sensitivity and specificity
of diagnostic tests, it can be employed to revise a diagnostic
assessment of a patient [10, 36, 37]. In this analysis I have used
the method to calculate the probability of various histopatho-
logic entities given data on the prevalence of the disorders that
could be affecting the patient, the frequency of disease manifes-
tations among these entities, and the clinical findings of the
patient under discussion.
In this particular case, the set of diseases under consideration
comprises 5 histopathologic entities (MN, MCD, FGS, MPGN,
and other). The prevalence of these 5 entities, termed here the
prior probabilities, was obtained from a review of several series
of patients with INS reported in the literature [3, 38—40]: the
data used for the prior probabilities are given at the top of Table
1. 1 selected clinical features of the nephrotic syndrome that
might be useful in discriminating among these histopathologic
entities. Experience in children indicates that these features do
help distinguish among histopathologic varieties [3, 41—43]. I
selected only clinical features, however, that appear to be
Table 1. Bayesian analysis for patient described
Histopathology MN MCD FGS MPGN Other
Prior probability .50 .25 .15 .08 .02
Conditional probabilities
Age, 45—60 years
Sex, female
Blood pressure,
<160/95 mm Hg
Serum creatinine, <1.5 mg/dl
Hematuria, microscopic
Complement, normal
.25
.43
.75
.85
.55
.98
.20
.50
.85
.95
.25
.98
.17
.34
.75
.75
.47
.94
.14
.63
.60
.60
.60
.35
.12
.40
.75
.85
.40
.85
Posterior probabilities .70 .19 .08 .02 .01
independent and unrelated manifestations. They included the
patient's age, sex, blood pressure, glomerular function, pres-
ence or absence of hematuria, and serum complement level.
These features are not the only ones with diagnostic value, but I
judged them the more important ones. The probability of finding
each of these clinical manifestations in the 5 histopathologic
entities is a conditional probability and is displayed in the
center of Table 1. For the sake of brevity, the only conditional
probabilities shown are those found in the patient under discus-
sion (for example, blood pressure less than 160/95 mm Hg, and
serum complement within normal limits). Again, these condi-
tional probabilities were obtained from a review of the reported
clinical manifestations of MN, MCD, and the other histopatho-
logic categories.
The revised or posterior probabilities of each of the five
histopathologic varieties of INS for the patient under discussion
are shown at the bottom of Table 1. Table 2 illustrates the
method of calculating the posterior probabilities from the prior
and conditional probabilities for a single clinical feature, micro-
scopic hematuria. To obtain the posterior probability of each
histologic entity given the presence of microscopic hematuria,
the product of the prior probability of each entity and the
conditional probability of microscopic hematuria in each is
divided by the sum of all the products of the prior and
conditional probabilities. After this result is obtained for micro-
scopic hematuria, the process is repeated for the remaining
conditional probabilities. Each time the process is repeated, the
posterior probability of the previous analysis is used as the prior
probability for the next analysis. The details of this process are
described elsewhere [10, 36]. In this patient the probabilities of
the various histopathologic entities used in Figure 1 are derived
from the posterior probabilities shown at the bottom of Table 1.
Complications of renal biopsy. With fluoroscopy or ultrason-
ography to localize the kidney, percutaneous needle biopsy
yields renal tissue in 95% of patients. I have assumed that the
tissue obtained by biopsy is suitable for pathologic analysis,
that is, that the specimen contains sufficient glomeruli. Only
one death was reported in combined data from 5 reports of more
than 3000 patients undergoing percutaneous biopsy. In addi-
tion, 2 patients required exploratory surgery because of hemor-
rhage [44—48]. The risk of complications was not influenced by
age or pathologic diagnosis. I also have assumed that the 5% of
patients in whom adequate renal tissue is not obtained undergo
a second percutaneous biopsy or an open surgical biopsy,
yielding an adequate specimen. Finally, I have assumed that the
566 Nephrology Forum
Table 2. Example of Bayesian analysis for one clinical feature (microscopic hematuria)
Revised probability
Prevalence of each Frequency of of each entity given
entity in a cohort of microscopic hematuria Product of prior microscopic
Histopathologic patients with INS in each entity and conditional hematuria
entity (prior probability) (conditional probability) probability (posterior probability)
MN .50 .55 .2750 .59
MCD .25 .25 .0625 .13
FGS .l5 .47 .0705 .15
MPGN .08 .60 .0480 .17
Other .02 .40 .0080 .02
Sum .4640
Table 3. Complications
Probabilities
(First-order
approximations)
Renal biopsy
Death
Serious nonfatal complications
Nephrotic syndrome5
Death from early complications
Serious, nonfatal, short-term complications
Steroid therapy (per course)a
Death
Serious nonfatal complications
0.0003
0.0006
0.001
0.050
0.001
0.050
a The ratios of serious nonfatal complications to death for nephrotic
syndrome, steroid therapy, and biopsy shown here were kept constant
in all sensitivity analyses.
b For patients with MCD who were treated with steroids, the
probabilities of death and serious nonfatal complications are reduced
50% to account for the reduction in these complications with steroid-
induced early remission.
As noted in the text, probabilities for complications of therapy are
obtained by multiplying the complication rates per course of treatment
by the average number of courses of treatment for each histopathologic
type. Average number of courses of steroids for the various histopatho-
logic lesions are: MN, 1.3; MCD, 2.5; FGS, 1.1; MPGN, 1.1; Other,
1.3.
small probability that a second biopsy will be necessary will not
increase the chance of serious complications. I have posited the
risk of death to be 0.03% and of serious complications to be
0.06% (Table 3).
The only utility in the primary tree is that of biopsy-related
death. This complication is considered to occur immediately
and its utility (measured in years of survival, see above) is thus
zero.
Nephrotic syndrome subtree
As noted, the nephrotic syndrome subtree is an extension of
multiple branches of both the primary tree and the steroid
therapy subtree. One uses the nephrotic syndrome subtree by
obtaining specific values for probabilities and utilities for out-
comes of each histopathologic variety of INS. In some in-
stances the outcomes differ depending on the response to
treatment. I now would like to explain how these data were
derived (Table 4).
Outcomes of untreated INS. Approximately 25% of untreat-
ed patients with MN experience a complete or partial remission
of the nephrotic syndrome within 2 years after the onset [38, 39,
49]. Approximately 40% of patients with persistent nephrotic
syndrome secondary to MN develop progressive renal insuffi-
ciency; the average time before renal failure develops in this
group is approximately 10 years [49, 50]. Approximately 50% of
untreated adults with MCD achieve a spontaneous remission of
proteinuria within 2 years [39, 50, 511. Progression to renal
failure in these patients is rare and is estimated at 1%. Typical-
ly, nephrotic syndrome in FGS is persistent, and in untreated
patients progressive renal insufficiency results in renal failure in
approximately 5 years on average t42, 52—57]. I estimate that
only 10% of such patients sustain a spontaneous remission of
the nephrotic syndrome and survive for prolonged periods
without renal insufficiency. Like those with FGS, patients with
MPGN have a poor prognosis; although normal renal function
persists in some patients for many years, total renal failure
develops on average in 5 years [3, 42, 58—611. I estimated the
spontaneous remission rate of MPGN to be the same as in FGS.
Glomerular lesions other than those considered above (other)
are rare causes of idiopathic nephrotic syndrome [40, 62—66].
Data are sparse in this group, but I have assumed the prognosis
in untreated patients to be the same as in those with FOS and
MPGN (see Table 4).
Complications of INS. Complications that occur early in the
course of nephrotic syndrome result in short-term morbidity;
these include infection, thromboembolism, vascular collapse,
and acute renal failure. Although these complications are
uncommon, each can lead to serious morbidity and even death.
Data on the frequency of these complications are limited, but I
have posited the risk of death and serious morbidity from early
complications to be 0.1% and 5%, respectively (Table 3). For
any individual who suffers one of the short-term, serious but
nonfatal side effects, the quality of life was decreased by
subtracting 0.1 QALY (Table 5). As noted before, the utility of
death from any of these side effects is zero.
Long-term complications resulting from the metabolic de-
rangements that accompany persistent nephrotic syndrome
include persistent edema, accelerated arteriosclerosis, early
bone demineralization, and side effects of diuretic therapy [671.
1 incorporated the impact of the complications by decreasing
the quality of life in all patients with persistent nephrotic
syndrome by multiplying the time interval over which these
patients are nephrotic by 0.90 (Table 5).
Development of total renal failure. In patients who develop
total renal failure, the average time before renal failure develops
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Table 4. Outcomes of nephrotic syndrome
Histopathology MN MCDi' FGS MPGN Other
Probability of sustained
remission
No steroid therapy .25 .50 .10 .10 .10
Steroid therapy .65 .50 .10 .10 .10
Probability of long-term pres-
ervation of normal renal
function
No steroid therapy .60 .99 .10 .10 .80
Steroid therapy .75 .99 .10 .10 .80
a The designation of MCD as a steroid-responsive lesion is based on
criteria other than these long-term outcomes. For explanation, see text.
is approximately 10 years in those with MN and 5 years in
patients with all other histologic varieties of INS. Thus, if renal
failure develops in the 60-year-old woman we are discussing, it
would not occur until she is 65 or 70 years old, depending on the
renal lesion. At either of these ages, I assume that maintenance
dialysis would be the only treatment available to her. The life
expectancy of a healthy 65- or 70-year-old woman is 18.4 years
and 14.8 years respectively [33], but that of a patient of her age
on dialysis is considerably reduced (6.3 years and 5.0 years
respectively) [681. Furthermore, the quality of life of a patient
treated with maintenance dialysis is reduced. I have assumed a
25% reduction in quality (Table 5); this figure conforms to
recent data obtained from such patients [691.
Steroid therapy subtree
The outcomes of steroid-treated INS versus untreated INS.
In a randomized double-blind trial of short-term, alternate-day
corticosteroid therapy (the Collaborative Study"), patients
received a course of 125 mg prednisone every other day for 2
months [38]. If an early partial or complete remission was
followed by a relapse of proteinuria after the prednisone dosage
was reduced, additional courses of therapy were given. The
average number of courses of steroid treatment in patients with
MN was 1.3 per patient. Within 2 years, 65% of patients with
MN achieved a complete or partial remission (Table 4). The
difference in frequency of renal failure in the initial report of the
Collaborative Study between untreated and treated groups was
23% [38]. In other studies of untreated patients [39, 49], early
progression to renal failure was less frequent than in the
untreated group in the Collaborative Study. In an attempt not to
overestimate the benefit of steroid therapy for MN, therefore, I
took the difference in frequency of early renal failure to be 15%.
Long-term results of the Collaborative Study are not yet
available, but data from ither studies indicate that long-term
survival in patients treated with corticosteroids is approximate-
ly 50% [50, 52, 70—74]. Only one-half of the deaths are due to
renal failure (25% of patients); the average time for progression
to uremia is approximately 10 years [50]. Based on these data, if
the 15% difference holds over 15 years, the fraction of patients
with MN developing end-stage renal disease within this time
would be approximately 40% in the untreated group and 25% in
the treated group (Table 4).
A review of 9 series comprising 208 adults with MCD who
were treated with daily steroid therapy (and in some cases
cytotoxic agents also) showed that 95% of patients experienced
Table 5. Adjustments for quality of life
Short-term (subtractive)
Complications of renal biopsy
Complications of the nephrotic state
Complications of steroid therapy
Value (years)
0.1
0.1
0.1
Long-term (multiplicative) Factor
0.90
0.75
Persistent nephrotic syndrome
Maintenance dialysis
early remission of proteinuria [511. Two patients (1%) devel-
oped renal failure, and 21(10%) died. Of the deaths, one-half
probably resulted from complications of treatment. Preliminary
findings of an ongoing trial suggest that alternate-day predni-
sone therapy (125 mg every other day for 2 months) is as
effective as daily steroid therapy [51]. Of 11 patients with MCD
treated with alternate-day steroids, 10 (91%) experienced com-
plete remission of nephrotic syndrome; the remaining patient
had a notable reduction in proteinuria. After 2 years, one-half
had followed a relapsing course and received multiple courses
of therapy. None had serious side effects of nephrotic syn-
drome, none developed renal failure, and none died. Thus,
adults with MCD have an excellent prognosis in terms of
survival and preservation of renal function, whether or not they
are treated with steroids. Steroid therapy appears to hasten
remission of nephrotic syndrome and reduce the frequency of
early complications. Because of this steroid-induced reduction
in short-term complications, MCD is considered a steroid-
responsive lesion. I assumed that the likelihood of early compli-
cations of nephrotic syndrome was reduced by 50% in patients
treated with alternate-day prednisone therapy (Table 3). Wheth-
er treatment prolongs life expectancy or reduces long-term
morbidity in adults with MCD remains uncertain. I assume here
that steroid therapy does not prolong life expectancy in MCD;
thus the probability of sustained remission was taken to be 50%
in treated as well as untreated patients (Table 4). I assumed that
relapsing patients received on average 4 courses of therapy;
thus, of all patients with MCD treated with steroids, on average
2.5 courses of therapy were given. The probability of progres-
sion to renal failure in patients with MCD was taken to be 1%.
In those who do progress, the mean time to the onset of uremia
was assumed to be 5 years.
Although a number of patients with FGS can experience a
temporary improvement in proteinuria after treatment, neither
corticosteroids, cytotoxic agents, nor any other form of therapy
appears to retard the progression to renal failure. A prospective
controlled study of short-term, alternate-day steroid therapy in
patients with FGS is in progress, but no data are yet available
[38]. For this analysis I assumed the probability of remission in
patients with FGS to be 10% whether or not steroid therapy is
given, and I further assumed that all patients not in remission
develop renal failure within 5 years on average. Sometimes
patients with FGS follow a relapsing course after treatment with
corticosteroids; I assumed this happens in 10% of steroid-
treated patients, resulting on average in 1.1 courses of therapy
per patient.
There is no evidence, at least from a pediatric study, that
steroids alter the course of MPGN predictably or reliably [75].
Therefore, I assumed that MPGN is a steroid-unresponsive
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Table 6. Time interval components of utilities (averageS)"
Years'
Age-, sex-, and race-adjusted life expectancy 22.3
Time until development of renal failure
MN 10
All other histopathologic types 5
Life expectancy from onset of renal failure in patient
treated only with maintenance dialysis
Onset of renal failure after 5 years of INS 6.3
Onset of renal failure after 10 years of INS 5.0
Life expectancy of patient who dies immediately of
complication of nephrotic state, biopsy, or steroid therapy 0
a These values apply only to the 60-year-old woman under discussion
in this Forum.
b The cost of short-term complications and of long-term quality-of-
life expectancy is not included in these figures.
histopathologic variety of INS; in steroid-treated patients I
assumed that patients received 1.1 courses of therapy on
average, that 10% of patients experienced a remission of
nephrotic syndrome, and that, on average, the remaining pa-
tients progressed to renal failure in 5 years.
In the other disorders (Other in Fig. 1), steroid therapy is not
usually effective in achieving a sustained reduction in urinary
protein excretion or in preventing renal failure [611. Thus this
heterogeneous group of disorders was classified as steroid-
unresponsive. I considered nephrotic syndrome persistent in
90% of these patients; I assumed that renal insufficiency occurs
in approximately 20% and progresses to renal failure in 5 years.
If treatment is given and the patient is in the small cohort that
responds to treatment, I assumed that 30% of patients have a
relapse of their disease; thus patients would receive, on aver-
age, 1.3 courses of therapy. Table 4 summarizes the data used
to define the outcomes of these 5 histopathologic varieties.
Complications of steroid therapy. Gastrointestinal bleeding
and urinary tract infection occurred in 2 of 34 patients with MN
treated with 125 mg prednisone every other day for 2 months
[38]. Because patients with MN received an average of 1.3
courses of therapy, the risk of serious complications per course
of treatment was 5% (2 of 34 patients per 1.3 treatments per
patient). In adults with MCD receiving alternate-day steroid
therapy, 3 of II developed severe complications [51]. Assuming
that these patients received an average of 2.5 courses of
therapy, the risk of severe complications was 11% per treat-
ment(3 of 11 patients per 2.5 courses of treatments per patient).
The higher complication rate per treatment might result from
cumulative toxicity of multiple courses of therapy.
Because data are limited regarding short-term, alternate-day
prednisone therapy in the other histopathologic varieties of
INS, I assumed the probability of complications from steroid
therapy in these disorders to be similar to that observed in
patients with MN and MCD. I made the simplifying assumption
that in all pathologic subtypes of INS, the risk of death and
serious complications per course of treatment was 0.1% and 5%
respectively (Table 3). I assumed that the frequency and
severity of complications depended only on the number of
courses of therapy. I obtained the probability of a complication
of therapy by multiplying these risks by the average number of
courses of treatment for each histopathologic type (1.3 for MN,
2.5 for MCD, 1.1 for FGS, 1.1 for MPGN, and 1.3 for others).
A fatal complication of steroid therapy was assumed to occur
immediately and was assigned a utility of zero. A nonfatal
complication was considered a short-term morbidity, and the
quality-of-life adjustment for this complication was performed
by subtracting a fixed amount of time (0.1 QALY) from the
quality-adjusted life expectancy. The data are displayed in
Table 5.
Sample utility calculations
If a 60-year-old patient receives only supportive therapy,
experiences a spontaneous remission of nephrotic syndrome,
and escapes any serious complications due to the nephrotic
syndrome, the utility expression for this outcome is simply
URemission the age-, sex-, and race-adjusted life expectancy,
or 22.3 years, because the "cost" of all complications is zero.
But let us consider a patient with MN who has no early
complications of steroid therapy, biopsy, or the nephrotic state,
who remains nephrotic, later develops total renal failure, and
then is treated indefinitely by dialysis. Two quality-adjusted
time intervals comprise the utility for a patient with these
outcomes. The first is the product of a 10-year nephrotic period
(Table 6) and a value of 0.9 for the quality of the nephrotic state
(Table 5), or 9.0 QALY. The second interval is the product of a
5-year life expectancy with dialysis for a 70-year-old woman
after the onset of end-stage renal disease (Table 6) and a value
for the quality of life on maintenance dialysis of 0.75 (Table 5),
or 3.8 QALY. Thus, the total utility for a patient with this
complex, albeit common, outcome is 9.0 + 3.8, or 12.8 QALY.
Results of the analysis
The decision tree and its subtrees were constructed using the
DECISION-MAKER computer program [76] and was run on a
PDP 11/03 computer. The tree and all its subtrees contained a
total of 381 nodes and 213 terminal branches. The calculation of
expected utility for all three choices was carried out in slightly
more than two minutes.
Expected utility calculations from baseline assumptions
The expected utilities of the three options are: (1) Administer
no steroid therapy, 17.7 QALY; (2) Perform renal biopsy and
treat (or not) depending on the histopathologic lesion found,
19.0 QALY; and (3) Give high-dose, alternate-day steroid
therapy, 19.0 QALY. Note that the expected utility of no
treatment is more than one year less than that of the other two
options, but no difference exists in expected utility between
treating "blindly" and using the biopsy-directed approach.
According to these calculations, the decision is a toss-up; that
is, there is no clear-cut best choice, yet there is a clear-cut
worst choice: no treatment [5].
Sensitivity analysis
Effect of the probability of steroid-responsive nephrotic syn-
drome. This analysis was carried out by varying the probability
of steroid-responsive nephrotic syndrome from 0 to 1 and
calculating the expected utility of all three options. To perform
this analysis, I kept the ratios among histopathologic varieties
in both the steroid-responsive group and steroid-unresponsive
group the same as those in the posterior probabilities (see Table
1). The sensitivity analysis was first carried out using baseline
estimates of the risks of biopsy and steroid therapy. Figure 4A
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Fig. 4. Sensitivity analyses showing quality-adjusted life expectancy for a range of probabilities of steroid-responsive nephrotic syndrome from 0.0
to 1.0. The analysis using "baseline" probabilities of biopsy and steroid mortality rates is shown on the left (A). In this figure the lines depicting the
expected utilities of the "biopsy" and "steroid therapy" options were superimposable and thus have been represented as a single line wider than
the "no therapy" (i.e., supportive therapy only) line. This result indicates that the options of biopsy-directed steroid therapy and blind steroid
therapy (i.e., treating all patients without biopsy) are nearly equivalent strategies (a "toss-up") no matter what the chance of steroid-responsive
nephrotic syndrome. Both these options, however, are superior to withholding steroid therapy. The analysis is repeated for an exceptionally high
steroid risk and zero biopsy risk in the figure on the right (B). Despite these unrealistic risk estimates, the optimal choice remains a toss-up between
biopsy and "blind" steroid treatment at most probabilities of steroid-responsive nephrotic syndrome. No treatment (supportive therapy) is the
least optimal choice, except for probabilities of steroid-responsive nephrotic syndrome less than 0.1, but at these low probabilities the choice
among all three options is a close call.
illustrates the results of this analysis. Note that no matter how
low the probability of steroid-responsive nephrotic syndrome,
the option not to treat never becomes the preferred choice. Also
note that the expected utilities of the other two options, "blind"
treatment and biopsy first, are inseparable at any probability of
steroid-responsive disease. Thus, no matter how likely steroid-
responsive nephrotic syndrome is in this 60-year-old woman,
the choice between treatment with steroids and the biopsy-
directed approach is a toss-up.
Effect of high risk of steroid therapy and no risk of biopsy. If
the probability of death ensuing from a 2-month course of high-
dose, alternate-day steroid therapy is arbitrarily set at 0.01 (an
unreasonably high value) instead of the baseline value of 0.001,
and if the probability of death from renal biopsy is set at 0.0, the
expected utilities of the three options are: (I) Administer no
steroid therapy, 17.70 QALY; (2) Perform renal biopsy and
treat according to histopathologic lesion found, 18.73 QALY;
and (3) Give high-dose, alternate-day steroid therapy, 18.72
QALY. The conclusion is the same as that described earlier:
biopsy and "blind" steroid therapy are virtually equivalent, but
each is better than no treatment at all.
If the sensitivity analysis on the probability of steroid-
responsive nephrotic syndrome is performed as described using
exceptionally high steroid risk and low biopsy risk (Fig. 4B), the
expected utility of the biopsy option is either equal to, or only
slightly higher than, the expected utility of the next best option,
but the difference in utility between biopsy and the next best
strategy is always small. Despite the high complication rate,
steroid therapy has a higher expected utility than does no
treatment, except for probabilities of steroid-responsive ne-
phrotic syndrome less than 0.1. The largest difference between
the option with the highest expected utility and the next highest
is 0.12 QALY, equivalent to approximately 6 weeks. This gain,
compared to an expected utility between approximately 10 and
20 QALY for any probability of steroid-responsive nephrotic
syndrome, is sufficiently small that the choice still should be
considered a toss-up.
Effect of better results of the treatment of MCD. The
analyses described were carried out under the assumption that
steroid therapy had no influence on the remission rate in
patients with MCD. In this sensitivity analysis, the rate of
sustained remission in MCD was varied between 0.5 (the
baseline value) and 1.0, and the analysis was repeated. The
expected utility of the blind treatment and the biopsy-directed
approaches remained virtually identical and always better than
the no-treatment option.
Effect of timing of steroid-induced complications. I per-
formed this analysis using baseline assumptions. I first assumed
that when a steroid-induced complication occurred, steroid
administration had to be discontinued and that the patient did
not derive any benefit from treatment. I then repeated the
analysis assuming that although the complication occurred, the
patient still achieved full benefit of treatment. Although the
expected utility of the treatment option improved if the compli-
cation occurred only after therapy, the change was insignifi-
cant. The choice between "blind" treatment and the biopsy-
directed approach remained a close call.
General comments
The decision tree used to analyze the optimal approach in this
patient could be made applicable to any patient with INS, but
the results of the analysis are germane only to the patient under
discussion today. Although most nephrologists would insist on
carrying out a renal biopsy in this patient before embarking on a
course of steroid therapy 11—4], the analysis provides convinc-
ing evidence that this view is unwarranted. Extensive sensitiv-
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ity analysis shows that the biopsy-directed approach, namely,
treating the patient only if she were shown to have a histopatho-
logic lesion known to be responsive to steroid therapy, is no
better than treating her with steroids without knowing the
histology [5]. Indeed, no matter how I biased the analysis to
exaggerate the risks of steroids and underplay the risks of
biopsy, the result was always the same: biopsy-directed and
"blind" treatment were virtually equivalent strategies. Even
when the probability of steroid-responsive nephrotic syndrome
was varied from very high to very low levels, the expected
utilities of the two strategies were still virtually the same.
Except when the probability of steroid-responsive INS was
very low, however, the option of withholding treatment was
substantially worse than the other two choices, This analysis
confirmed the common attitude that withholding steroid thera-
py is not the optimal approach.
What approach should one take in a patient, such as the one
under discussion today, when the choice between biopsy and
"blind" steroid therapy is a toss-up? This question can best be
answered if we examine the biases of the assumptions used in
formulating the analysis. Two such assumptions are pertinent:
first, that biopsy precisely identifies the histopathologic varie-
ties of INS, and second, that biopsy carries with it no financial
expense. Although I assumed that the histologic type of INS is
always identifiable, even expert renal pathologists disagree
about the classification of renal lesions in patients with INS
[77]. For this reason, errors are inevitable when a biopsy is
interpreted, and such errors reduce the expected utility of the
biopsy option. Second, the expense of renal biopsy must be
considered. Although the patient under discussion had third-
party coverage and would not have directly paid for the biopsy,
any expenses of renal biopsy reduce its value to the patient. At
present, the charges for a 2- to 3-day admission for an uncompli-
cated renal biopsy at the New England Medical Center are
approximately $2500 to $3000. Thus, if the choice between
biopsy and "blind" steroid treatment is a close call, the error in
biopsy interpretation as well as the associated expense would
reduce the value of the biopsy option and leave "blind" steroid
therapy as the optimal choice. This conclusion would be even
stronger if the patient were at a hospital in which the patholo-
gists were less expert and at which the risks of biopsy were not
as low as those used in this analysis.
It is interesting that the choice between biopsy and "blind"
treatment is a toss-up for this patient no matter what the chance
of the patient having steroid-responsive nephrotic syndrome,
that is, either MN or MCD. This conclusion implies that the
same result might be obtained for any patient with INS. This
question will require a more extensive analysis using a decision
tree similar to that used here, but applied to patients of both
sexes and of various age groups. For younger patients, the renal
failure branch would require expansion to encompass changes
in life expectancy associated with cadaver donor and living
donor transplants. My colleagues and I are in the process of
performing such a study now.
If, as seems likely, the results of a generic analysis of all
patients with INS prove similar to the conclusions for this
patient, what can we deduce about the traditional practice of
biopsying the kidney before treating? The reduction of diagnos-
tic uncertainty by a relatively safe test (biopsy) comforted
physicians with the knowledge that they were treating only the
responsive forms of the syndrome and avoiding unnecessary
therapy in patients who would not benefit from steroids. The
theory was rational, but the observation that treatment with
steroids on an every-other-day basis was as effective but safer
than daily steroid therapy [38, 51] might have been used as a
basis for adopting the "blind" steroid therapy approach. Clini-
cians did not alter their management approaches, however,
perhaps because the tradition of biopsying first had become
firmly entrenched, and perhaps because physicians are uncom-
fortable with uncertainty. Obviously, it is disquieting to be
treating all patients with a drug to which only some will
respond.
Some clinicians argue that a need for "baseline" data neces-
sitates renal biopsy early in a patient's course. This argument
implies that although early decision-making would not be
affected by the information gained at biopsy, important thera-
peutic decisions later would depend on such information. I
doubt that this assertion is valid. Let us follow a "what-if"
examination of patients treated "blindly" with steroids and try
to imagine what advantage specific histopathologic data might
confer. (1) If we blindly treat a patient who has INS with
steroids, and proteinuria remits, we would taper the steroids
and stop treatment. We would do this no matter what the
histopathology. (2) If proteinuria remits while the patient is
taking steroids but the proteinuria then recurs, we again would
treat with steroids no matter what the lesion. (3) If a patient's
disease fails to remit, we would stop giving steroids after the 2-
month course, no matter what the lesion. (4) If, later in the
patient's course, progressive renal failure develops, we would
not treat the patient again with steroids; there is no evidence
that this approach has any value. Again, this decision would not
depend on the renal lesion. (5) Finally, one could argue that still
later in the course the histologic data could be useful in
choosing between dialysis and transplantation. Certain types of
renal lesions, such as focal glomerulosclerosis, do have a
tendency to recur after transplantation, and others do not. But
again I doubt that the histologic information would change the
decision between dialysis and transplantation. Most patients
choose between these two treatment modalities on the basis of
other factors, and most nephrologists regard transplantation in
patients with focal glomerulosclerosis as a reasonable option
even though there is an increased chance of recurrence in the
transplanted kidney. Only when the patient and physician are
undecided about this choice would such information be helpful.
In such circumstances a renal biopsy performed when the
patient is already uremic would be of little diagnostic value,
because the advanced histologic changes of chronic renal
disease might well obscure the diagnosis. Nonetheless, I be-
lieve that these dilemmas are rare. I do not believe that the
information from renal biopsy is sufficiently valuable later in the
patient's course to justify performing the test when the patient
first presents with the syndrome.
What are the implications for the research efforts currently
underway to determine the optimal approach to INS? Even if a
generic analysis shows that the choice between biopsy and
"blind" treatment is a toss-up for all patients with INS, the
conclusion that the biopsy-directed approach offers no benefit
over "blind" treatment would be applicable only to patients
being treated by physicians not engaged in this research.
Research efforts to identify optimal therapeutic approaches
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must continue, because more effective treatment regimens will
be devised through such efforts. Indeed, such regimens could
be assessed by how much they widen the life expectancy in
treated and untreated groups.
The analysis discloses several features about the manage-
ment of INS that are worthy of comment. First, the risk of both
steroid therapy and biopsy is very small, but given the low risk
of alternate-day steroid therapy, little harm is done by treating
all patients, thus exposing the patients with steroid-unrespon-
sive lesions to unnecessary therapy. On average, inappropriate
therapy in steroid-unresponsive patients is a small price to pay
for the remissions induced in the steroid-responsive patients. Of
course it is true that the risk of renal biopsy is also small, and
one could argue equally cogently that a renal biopsy should be
done in all patients: even though the patients who ultimately
receive steroid therapy anyway will be biopsied unnecessarily,
there is some benefit to be gained—that is, the avoidance of
steroid therapy—in the patients found to have one of the lesions
that generally do not respond to steroids. Given the low risks
and modest benefits with both renal biopsy and "blind" steroid
therapy, the choice between the two options is a close call.
The finding that "blind" steroid therapy is at least as good as
the biopsy-directed approach in the patient under discussion
today, no matter what the chance of a steroid-responsive lesion,
is surprising; one would expect that "blind" therapy would be
preferable for patients with a high probability of steroid-
responsive INS, that is, those highly likely on clinical grounds
to have either MN or MCD, and one would predict the biopsy-
directed approach to be preferable in patients with a small
chance of having steroid-responsive INS. Indeed, these prefer-
ences are revealed in the analysis, but the differences in
expected utility between the two options are extremely small no
matter what the chance that the patient has a steroid-responsive
lesion. Whether the differences will remain as narrow when the
analysis is extended to patients of both sexes and all age groups
remains to be assessed.
Finally, every part of the analysis presented here is open for
discussion and scrutiny. The difference between this Forum and
the usual discussions we have about the value of renal biopsy is
that here I have stated specifically all my assumptions, all my
biases, all the outcomes that I consider relevant, and all the data
I used to solve the problem. There are hundreds of assump-
tions, most of them based on published data on INS and some
on my own perceptions and prejudices about outcomes of the
syndrome, and they are all displayed here. Indeed, one of the
most attractive features of decision analysis is its explicitness.
If there is disagreement about any of the data or the assump-
tions, we can simply rerun the computer program using differ-
ent, but still explicit, estimates and determine whether the
decision for this patient changes.
Questions and answers
DR. JOHN T. HARRINGTON: Dr. Herrin, what do you think
would be the impact of following Dr. Kassirer's analysis on the
pediatrician's approach to nephrotic syndrome?
DR. JOHN T. HERRIN (Chief, Pediatric Nephrology, Massa-
chusetts General Hospital, Boston): An analysis such as that
outlined by Dr. Kassirer would not change the common pediat-
tic practice of treatment with steroids, reserving renal biopsy
for those patients who fail to respond, relapse frequently, or are
steroid dependent. The high probability of minimal-change
lesion in childhood nephrotic syndrome is likely to weigh the
result even more favorably to "blind" steroid trial in childhood
than in adulthood.
It might be reasonable to look at selectivity of proteinuria as a
guide to the need for renal biopsy before treatment. Highly
selective proteinuria generally is associated with steroid re-
sponse, whereas patients with nonselective proteinuria rarely
respond to steroid therapy. Maybe it would be reasonable to
use nonselective proteinuria as an indication for biopsy. Pa-
tients with highly selective or moderately selective proteinuria
then could be given a steroid trial, and biopsy could be reserved
for those who fail to respond.
DR. KASSIRER: My analysis does not address whether protein
selectivity is a useful test for all patients with INS, but in the
patient analyzed in today's Forum, the presence or absence of
selective proteinuria would not have had an effect on the
decision. The only effect the result of such an analysis of urine
protein has is altering the probability of steroid-responsive
nephrotic syndrome. As Dr. Herrin correctly asserted, the
finding of selective proteinuria increases the probability of a
steroid-responsive lesion, and the finding of nonselective pro-
teinuria reduces it. For this patient, the choice between biopsy
versus "blind" steroid therapy was insensitive to the probabili-
ty of a steroid-responsive lesion; that is, the biopsy and
treatment options were of equivalent value no matter what the
chance of a steroid-responsive lesion. Given this result, the
measurement of protein selectivity would provide no additional
information that would influence the decision, and in this
patient we could find no justification for doing the test.
If a generic analysis of INS eventually shows a definite
preference for biopsy in patients with a moderate to high
probability of steroid-responsive nephrotic syndrome, then
diagnostic tests that help discriminate among the various histo-
pathologic varieties of INS, such as protein selectivity studies,
will be useful because they will increase or reduce our belief
that the lesion is a responsive one.
DR. NIcoLAos E. MADIAS: Of the various factors tested in
the sensitivity analysis, which was the most important in
affecting the outcome?
DR. KASSIRER: If! took what I considered extreme estimates
for the risks of steroids and biopsy, and extreme estimates for
the steroid responsiveness of the various lesions, the results
were still the same. Figure 4B shows an example of this kind of
analysis for a high-steroid and low-biopsy risk. If you take
unreasonable values for the risk of steroids, for example, you
can demonstrate, as you might expect, that one of the other
options becomes preferable.
DR. HARRINGTON: What would the risk of steroid therapy
have to be for one to decide in favor of biopsy? What value for
the risk of steroids would be required to obtain a one-year
difference in quality-adjusted survival between "blind" steroid
therapy and the next best option?
DR. KASSIRER: The steroid mortality rate would have to be
approximately 10% to obtain a one-year difference in quality-
adjusted life expectancy between the "blind" steroid therapy
option and the next best alternative, which is withholding
therapy. This is clearly an unreasonably high value.
DR. JOSEPH LAU (Fellow, Clinical Decision-Making Division,
NEMC): We performed another analysis that addresses this
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Fig. 5. Course of the 60-year-old patient with
INS presented in this Forum. Note that
although the renal biopsy showed focal
glomerulosclerosis, prednisone therapy
produced a complete remission of the
nephrotic syndrome; when a relapse occurred
16 months later, prednisone again eliminated
proteinuria. The biopsy result in the patient
was misleading; initially she was not treated
with steroids because FGS was found, but
steroids were given when severe edema
became unmanageable. The result (complete
remission) was surprising.
issue indirectly by examining the impact of daily rather than
alternate-day steroid therapy. In that analysis we assumed a
mortality rate of 0.1% and an overall complication rate of 10%
for such therapy. Even in that extreme case, we found little
difference between biopsy and a trial of steroid therapy. In fact,
a therapeutic trial still was slightly preferable. We performed
this analysis to investigate the origin of the tradition of renal
biopsy; maybe in an era with higher steroid-related morbidity,
biopsy might have been preferable. However, to our surprise,
this was not the case.
DR. ALBERT FOURNIER (Chief, Nephrology Unit, Centre
Hospitalo-Universitaire, Amiens, France): Some nephrologists
believe that the response rate in MN is lower than that found in
the Collaborative Study [38j. If so, would your conclusion
change?
DR. KASSIRER: When I ran the computer program assuming
that no long-term benefit was derived from steroids in MN, I
found that the "no therapy" option was preferable by a small
margin (approximately 0.2 QALY) and that again the biopsy
and "blind" treatment approaches were virtually equal. Thus
more studies are needed to clarify the benefits of steroid
therapy in the so-called steroid-responsive varieties of INS.
DR. JEANINE CARLSON (Fellow, Division of Nephrology,
NEMC): On the basis of this Forum, it would appear that you
would not have recommended a biopsy for the patient present-
ed today. Was a biopsy performed and, if so, could you tell us
what it showed, how the patient was treated, and the eventual
outcome?
DR. KASSIRER: This patient was first examined several years
ago. She was managed according to the traditional approach
and was admitted to the New England Medical Center for renal
biopsy shortly after having been seen in the Nephrology Clinic.
Biopsy was carried out without complications. On light micros-
copy, one glomerulus was totally sclerotic, 19 others were
segmentally sclerotic, and others appeared normal. Immunoflu-
orescent microscopy showed focal segmental deposition of
1gM, complement, and fibrinogen in the glomeruli, and focal
deposits of C3 in tubular basement membranes and small
arterioles. Electron microscopy revealed extensive glomerular
epithelial foot process fusion and focal areas of glomerular
capillary collapse and sclerosis. No deposits were seen. All
findings were consistent with the diagnosis of focal glomerular
sclerosis.
Given the unequivocal diagnosis of FGS, steroid therapy was
not given and attempts were made to reduce the edema, which
was making the patient uncomfortable. Initially the diuretic
program was successful, but the patient became intolerant to
both furosemide and ethacrynic acid. In a few weeks despite
maximum doses of metolazone, spironolactone, mannitol, and
albumin, no further diuretic response could be obtained. In the
hope that steroid therapy might improve the patient's diuretic
responsiveness either by reducing protein excretion or by a
mechanism independent of proteinuria, she was started on
prednisone, 125 mg on alternate days. Her response to this
regimen was surprising. As noted in Figure 5, she had a
dramatic response to steroid therapy. Even though one would
have predicted from the biopsy findings that there would be no
response, proteinuria disappeared. Indeed, steroids had the
same effect on a second occasion after the nephrotic syndrome
recurred. Even though this response to steroids is unusual in
FGS, this patient would have benefited from "blind" treatment
if that approach had been accepted as the usual therapy when
she first presented.
DR. LAU: Dr. Kassirer, you didn't refer to the decision
analysis on idiopathic nephrotic syndrome reported by Hlatky
in the Lancet in December 1982.
DR. KASSIRER: I omitted a discussion of Hlatky's paper [78]
because I believe the study to be seriously flawed. It really isn't
a report of decision analysis, only of a probability analysis; and
because he took this approach, he did not represent all out-
comes such as remissions and complications on the same scale,
as I did. As a consequence, it is impossible to compare the
values of each management approach. Hlatky concluded that
"blind" treatment was better than renal biopsy-directed thera-
py, but because of the lack of a commensurate utility scale, it is
not possible to ascertain whether the two choices are a toss-up.
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I am also unhappy with his assessment of the response to
steroid therapy. He took the benefit of treatment in children as
a percent reduction in mortality compared to older studies and
extrapolated these results to adults. This assumption is
questionable.
Finally, he used the response rate after 2 months as the only
benchmark of successful therapy. I doubt that many nephrolo-
gists accept this assumption.
DR. ANDREW S. LEVEY (Division of Nephrology, NEMC): A
minority of patients with lesions traditionally classified as
steroid-unresponsive have been reported as having remissions
of proteinuria, or improvement in renal function or glomerular
pathology after steroid therapy. In view of these findings, some
nephrologists would try a short course of steroid therapy even if
the biopsy demonstrated focal sclerosis or MPGN. Would you
comment on how this strategy would alter the outcome of the
analysis for this patient?
DR. KASSIRER: Because the biopsy option and the "blind"
treatment option are equivalent for virtually any probability of
steroid response in nephrotic syndrome, that approach sounds
rational for the patient we are discussing today, but I am not
comfortable about extrapolating this notion to all patients with
INS unless the analysis is extended to include patients of all
ages. Recall that our group has not done a generic analysis for
all of INS. In the analysis today, I haven't included long-term
outcomes in patients who would receive renal transplants; all I
have considered is what happens in patients who develop renal
failure and are treated only with dialysis. If the results of an
analysis of the entire population of adults with nephrotic
syndrome turns out the same as the one here, then what you are
suggesting would be rational.
DR. MARTIN GELMAN (Renal Division, St. Elizabeth's Hospi-
tal, Boston): I was struck by the fact that there was only a one-
year difference between no treatment and treatment. For pa-
tients like the one presented, I would have assumed that a
satisfactory response to steroids would extend the life expec-
tancy considerably longer than that. Could you comment on
this apparent discrepancy?
DR. KASSIRER: Indeed, if the patient we discussed today had
responded to steroids and had had a permanent remission of
nephrotic syndrome, her quality-adjusted life expectancy would
be the optimal value of 22.3 years. If she had not responded to
steroids, had continued to have persistent nephrotic syndrome,
had had one or more serious complications, and had developed
renal failure after a few years, she would have had one of the
bad outcomes, a life expectancy of only 4 or 5 years. But in a
decision analysis, the expected utility of an option represents an
average value of each of the choices factored for the probability
of each outcome. For this reason the difference in average
value, or expected utility, between two therapeutic choices will
be much narrower than that between the best and worst
outcomes. So we shouldn't be confused between the average
life expectancy given the choices for a cohort of similar patients
and individual outcomes.
DR. MADIAS: Have you considered the impact of the prog-
nostic information derived from renal biopsy on the patient's
quality of life?
DR. KASSIRER: We could incorporate the prognostic value of
biopsy results into the analysis by adjusting the quality of life of
a patient who has access to the result. For any patient who has
had a renal biopsy and is found to have one of the favorable
lesions, such as MCD or MN, we could temporarily increase
the quality of the patient's life to reflect the patient's knowJedge
that the long-term prognosis is good. Of course, we would have
to temporarily reduce the quality of life for the biopsied patients
who do not have a steroid-responsive lesion. I haven't carried
out such an analysis, but it is difficult to imagine that this
modification would change the result.
Actually, considerable information is obtained from steroid
therapy. If the patient responds to steroids, there is a good
chance that the patient's long-term outlook is excellent. If the
patient fails to respond, the chance that normal renal function
will be preserved for many years is considerably reduced.
DR. HERRIN: I would agree that in fact we obtain better
information from steroid therapy than from biopsy. By that I
mean that a patient with any lesion does better if the lesion is
steroid responsive.
DR. JERRY MCCAULEY: (Nephrology Division, NEMC): You
have presented rather convincing evidence against renal biopsy
in idiopathic nephrotic syndrome. In most forms of secondary
nephrotic syndrome, little additional information is provided by
biopsy. Do you believe that renal biopsy should be relegated to
a research tool in nephrotic syndrome?
DR. KASSIRER: From the data I presented today, I would not
be willing to extrapolate that far. We need to expand the
analysis to a larger spectrum of patients before coming to grips
with your interesting question. As your question anticipates,
however, I am not convinced that renal biopsy provides much
information that is critical from a therapeutic standpoint in
many disorders including acute renal failure, lupus nephritis,
and nephrotic syndrome. But I would not be willing to make
this assertion with confidence without carrying out an analysis
of these different disorders.
DR. LEVEY: Biopsy does not appear to be a valuable tool for
this patient because our tests and therapies are neither very
good nor very harmful. If, for example, we had a magic bullet
that could cure focal sclerosis, but this treatment had important
toxicities, it would be important to find every patient with focal
sclerosis and to withhold this treatment from those with other
histologic types. Biopsy would then be a critical determinant of
therapy. The lack of utility for the biopsy in this case is simply a
reflection of the limited number of safe but effective therapeutic
modalities available for treating nephrotic syndrome.
DR. KASSIRER: Your point is well taken. It is an addendum to
a comment that I made in my discussion with regard to research
efforts in the field. There is no question that we need better
treatment for various types of nephrotic syndrome.
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